ixekizumab   

GtoPdb Ligand ID: 7541

Synonyms: LY-2439821 | LY2439821 | Taltz®
ixekizumab is an approved drug (FDA & EMA (2016))
Compound class: Antibody
Comment: Ixekizumab binds to IL-17A and blocks its action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A protein BLAST search using the variable region of the heavy chain of ixekizumab identifies this as sequence 118 from patent US7838638 [1]. In this patent binding affinity data for human IL-17 is provided for several antibody clones, but it does not specify which was chosen as ixekizumab, although mAbs 126, 121 and 104 did undergo additional experimental investigations.
No information available.
Summary of Clinical Use
Ixekizumab is approved for the treatment of psoriasis. Positive results from a Phase 2 study are reported in [6], and Phase 3 results are reviewed in [5]. In March 2016, the US FDA approved ixekizumab for the treatment of moderate-to-severe plaque psoriasis. The EMA granted marketing authorisation in April 2016.
Phase 3 results following 60 weeks of treatment are reported in [8], showing longer term efficacy (with ~80% of patients seeing at least a 75% improvement in their skin symptoms at 60 weeks).
Mechanism Of Action and Pharmacodynamic Effects
The IL-17 pathway is an established driver of psoriasis pathogenesis [7,9]. Ixekizumab effectively neutralises circulating IL-17A and reduces IL-17-induced pro-inflammatory signalling. This leads to an improvement in clinical disease symptoms. .
External links